"Designing Growth Strategies is in our DNA"

U.S. Dermatophytic Onychomycosis Treatment Market Size, Share & COVID-19 Impact Analysis, By Product Type (Tablets, and Nail Paints), By Route of Administration (Oral, and Topical), By Type (Prescription, and Over-the-Counter (OTC)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Channels), and Country Forecast, 2023-2030

Region : USA | Format: PDF | Report ID: FBI108477



Play Audio Listen to Audio Version

The U.S. dermatophytic onychomycosis treatment market size was worth USD 1.89 billion in 2022 and is projected to grow at a CAGR of 8.1% during the forecast period.

Onychomycosis is a common fungal nail disease affecting the general population of the U.S. Most infections are caused by dermatophytes. Furthermore, various studies have shown that the risk of developing onychomycosis increases with age. Additionally, people suffering from diabetes and immunosuppression are at great risk of developing nail infections.

  • According to the Centers for Disease Control and Prevention (CDC) data, onychomycosis affects approximately 14% of the general population of the country.

Thus, the rising prevalence of onychomycosis infections, a surge in the geriatric population, an increase in the diabetic population, and other factors supporting the U.S. dermatophytic onychomycosis treatment market growth. However, due to the COVID-19 pandemic, there was a reduction in patient visits. Moreover, the temporary closure of dermatology clinics during the pandemic resulted in delayed diagnosis, thus negatively impacting the market.


Rising Preference for Topical Solutions is a Prominent Trend in the Market  

At present, patients are gradually shifting their preference toward topical treatment solutions. Oral antifungal drugs for onychomycosis treatment are accompanied by systemic side effects and hepato-toxicity, and other side effects. The rising preference for topical solutions created significant market opportunities for manufacturers to increase R&D for developing and launching effective nail lacquers and topical drugs.

  • For instance, in April 2020, Bausch Health Companies Inc. received approval from the U.S. FDA for its efinaconazole topical solution 10%, “Jublia,” for treating fungal infections of toenails.


Growing Prevalence of Dermatophytic Onychomycosis to Propel the Demand  for the Treatment

The rising prevalence of dermatophytic onychomycosis in the country is one of the prominent factors increasing the demand for effective treatment and management of the condition. According to various research studies, it has been demonstrated that the risk of developing onychomycosis increases with age.

  • According to a study published by National Centers for Biotechnology Information (NCBI) in 2022, the prevalence of onychomycosis is more than 20% in people aged 60 years and above and more than 50% in adults aged 70 years and above.

Further, as per the data published by the World Bank Group, approximately 17.0% of the U.S. population is aged 65 years and above. Thus, the presence of a large target population is projected to augment the market growth.

Request a Free sample to learn more about this report.

According to the research articles published in the National Institute of Health, the prevalence of onychomycosis among the U.S. population is approximately 3.0%. The disease is more prevalent in men compared to women. The prevalence of onychomycosis (tines unguium) is 4.0% in male and around 1.7% in female.


Low Awareness Coupled with Side Effects Associated with Medications to Hamper the Market Growth 

Most people affected with onychomycosis infection are unaware of the condition and do not take treatment as the condition is not severe and life-threatening. Moreover, the drugs are associated with various side effects, such as headache, itching, diarrhea, skin blisters, and others.

  • According to the FDA data, the side effects of Jublia occurred in 1%-2% of the patients and comprised inflammation, skin rash, ingrown toenails, itchy skin, and pain.

Thus, the above-mentioned factors are likely to hamper the adoption of drugs for dermatophytic onychomycosis treatment, thereby impeding the market growth.


By Product Type Analysis

Based on product type, the market is segmented into tablets, and nail paints. The tablets segment is anticipated to grow at a significant CAGR during the forecast period. The higher efficacy of tablets dermatophytic onchomycosis treatment, is one of the key factors promoting the segment’s growth in the forthcoming years.

  • According to an article published in NCBI in 2022, tablets are intended for use in moderate to severe fungal diseases and exhibit a high cure rate. As per the article, Terbinafine (Lamisil) is 70% -79% effective in treating fingernail and toenail onychomycosis.

By Route of Administration Analysis

Based on route of administration, the market is categorized into oral and topical. The topical segment accounted for the largest U.S. dermatophytic onychomycosis treatment market share in 2022. Topical drugs are cost-effective and associated with fewer side effects, thus, increasing their adoption for the treatment of dermatophytic onychomycosis. Moreover, growing research for developing novel topical drugs is anticipated to bolster the market growth. 

  • For instance, NovaBiotics Inc., a clinical-stage biotechnology company, is developing a topical NP213 solution for nail disorders such as onychomycosis. NP213 (Novexatin) is a novel peptide developed from the company’s proprietary technology platform.

By Type Analysis

Based on type, the market is categorized into prescription, and over-the-counter (OTC). The OTC segment accounted for the highest market in 2022. The wide availability of the onychomycosis drug over the counter, sifting preferences towards nail lacquers, increasing OTC drug sales, and easy access to essential medication from the OTC are a few factors supporting the segment’s growth.

  • According to the Consumer Healthcare Products Association, in 2022, over-the-counter drug retail sales were about USD 41.2 billion.

By Distribution Channel Analysis

Based on distribution channel, the market is divided into hospital pharmacies, retail pharmacies, and online channels. The retail pharmacies segment held the largest share in 2022, owing to the increase in the sales of OTC onychomycosis medications. Furthermore, expanding retail pharmacies in the country is contributing to the market's growth.

  • For instance, in May 2021, Amazon announced opening its brick-mortar retail pharmacy in the U.S. Through this inorganic activity, the company is expanding its services in the physical pharmacy business segment.


This market is fragmented, with various players operating in the market. Bausch Health is one of the major players. The company has launched Jubila, a topical solution for toenail fungal infection. The cure rate of the product is about 15.0% -18.0%, which increased its adoption and increased the sales of the company.

Furthermore, other factors, such as the company's strong presence in the country and increasing R&D activities to develop novel drugs, among others, also strengthen the company’s market share. Some other companies operating in the market are, Pfizer, Inc., Johnson & Johnson Services, Inc., and others.



  • December 2021- American Podiatric Medical Association (APMA) approved Jublia developed by Bausch Health Companies Inc. The drug also received extended FDA clearance in 2020 for treating pediatric and adult patients suffering from onychomycosis.

  • July 2021- Lupin launched a generic topical solution, Tavaborole, in the U.S. The topical solution is equivalent to topical Kerydin intended for treating onychomycosis of toenails caused due to trichophyton rubrum or trichophyton mentagrophytes.

  • April 2021 - Aleor Dermaceuticals received the FDA clearance for efinaconazole topical solution for treating fungal toenail infections.


An Infographic Representation of U.S. Dermatophytic Onychomycosis Treatment Market

To get information on various segments, share your queries with us

The market report provides a detailed analysis of the market. It focuses on key aspects such as leading companies, competitive landscape, product type, and application. Besides this, it offers insights into the market trends and highlights key industry developments. In addition to the factors mentioned above, the report encompasses several factors that have contributed to the growth of the market over recent years.

Report Scope & Segmentation



Study Period


Base Year


Estimated Year


Forecast Period


Historical Period


Growth Rate

CAGR of 8.1% from 2023 to 2030


Value (USD Billion)


By Product Type

  • Tablets

  • Nail Paints

By Route of Administration

  • Oral

  • Topical

By Type

  • Prescription

  • Over the Counter (OTC)

By Distribution Channel

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Channels

Frequently Asked Questions

Fortune Business Insights says that the U.S. market was worth USD 1.89 billion in 2022.

The market is expected to exhibit a CAGR of 8.1% during the forecast period (2023-2030).

By route of administration, topical segment accounted for the leading proportion of the market.

Bausch Health Companies Inc. and Pfizer Inc., and others are the key players in the market.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts

Speak to an Expert
  • Oct, 2023
  • 2022
  • 2019-2021
  • 0

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Client Testimonials

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.